Aptahem AB (publ) (APTA.ST)
SEK 1.62
(0.0%)
SEK 1.62
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -11.11 Million SEK | -25.36% |
| 2022 | -8.86 Million SEK | 68.87% |
| 2021 | -28.47 Million SEK | -17.3% |
| 2020 | -24.27 Million SEK | -38.74% |
| 2019 | -17.49 Million SEK | 15.05% |
| 2018 | -20.59 Million SEK | -101.5% |
| 2017 | -10.22 Million SEK | -4.97% |
| 2016 | -9.73 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.63 Million SEK | 3.48% |
| 2024 Q1 | -2.72 Million SEK | 36.07% |
| 2023 FY | -11.11 Million SEK | -25.36% |
| 2023 Q2 | -2.73 Million SEK | -8.7% |
| 2023 Q3 | -1.59 Million SEK | 41.85% |
| 2023 Q4 | -4.26 Million SEK | -168.32% |
| 2023 Q1 | -2.51 Million SEK | 19.82% |
| 2022 Q2 | -1.79 Million SEK | 5.53% |
| 2022 FY | -8.86 Million SEK | 68.87% |
| 2022 Q4 | -3.13 Million SEK | -54.25% |
| 2022 Q3 | -2.03 Million SEK | -13.5% |
| 2022 Q1 | -1.89 Million SEK | 70.21% |
| 2021 Q3 | -5.15 Million SEK | -8.73% |
| 2021 FY | -28.47 Million SEK | -17.3% |
| 2021 Q2 | -4.74 Million SEK | 0.0% |
| 2021 Q4 | -6.37 Million SEK | -23.58% |
| 2020 FY | -24.27 Million SEK | -38.74% |
| 2019 FY | -17.49 Million SEK | 15.05% |
| 2018 FY | -20.59 Million SEK | -101.5% |
| 2017 FY | -10.22 Million SEK | -4.97% |
| 2016 FY | -9.73 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| 2cureX AB (publ) | -32.51 Million SEK | 65.825% |
| Abliva AB (publ) | -95.5 Million SEK | 88.365% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 89.832% |
| AcouSort AB (publ) | -17.08 Million SEK | 34.971% |
| Active Biotech AB (publ) | -45.8 Million SEK | 75.736% |
| Alzinova AB (publ) | -16.48 Million SEK | 32.568% |
| Amniotics AB (publ) | -30.87 Million SEK | 64.001% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 74.774% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 13.37% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 95.53% |
| BioInvent International AB (publ) | -330.3 Million SEK | 96.636% |
| BioArctic AB (publ) | 229.24 Million SEK | 104.848% |
| Biosergen AB | -27.03 Million SEK | 58.898% |
| Biovica International AB (publ) | -124.82 Million SEK | 91.097% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 80.442% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 97.616% |
| Camurus AB (publ) | 431.44 Million SEK | 102.576% |
| Cantargia AB (publ) | -280.02 Million SEK | 96.032% |
| Corline Biomedical AB | -1.8 Million SEK | -514.31% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 47.31% |
| CombiGene AB (publ) | -35.66 Million SEK | 68.841% |
| Cyxone AB (publ) | -22.98 Million SEK | 51.66% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 4.839% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 92.682% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 96.601% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 32.23% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 87.842% |
| Fluicell AB (publ) | -26.55 Million SEK | 58.15% |
| Genovis AB (publ.) | 61.5 Million SEK | 118.07% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 90.194% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.664% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 90.97% |
| Mendus AB (publ) | -101.61 Million SEK | 89.064% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 93.751% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 70.023% |
| I-Tech AB | 20.2 Million SEK | 155.006% |
| Intervacc AB (publ) | -102.85 Million SEK | 89.195% |
| Kancera AB (publ) | -64.88 Million SEK | 82.874% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 306.329% |
| LIDDS AB (publ) | -40.2 Million SEK | 72.36% |
| Lipum AB (publ) | -37.17 Million SEK | 70.109% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 8.37% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 191.321% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 37.907% |
| Nanologica AB (publ) | -75.15 Million SEK | 85.214% |
| NextCell Pharma AB | -41.95 Million SEK | 73.515% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 95.539% |
| OncoZenge AB (publ) | -15.9 Million SEK | 30.117% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -11.912% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 32.743% |
| Saniona AB (publ) | -95.81 Million SEK | 88.401% |
| Simris Alg AB (publ) | -37.3 Million SEK | 70.211% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 73.681% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -2437.185% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 53.183% |
| SynAct Pharma AB | -215.81 Million SEK | 94.851% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 96.426% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 97.137% |
| Xintela AB (publ) | -54.08 Million SEK | 79.452% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 93.815% |
| Ziccum AB (publ) | -21.41 Million SEK | 48.1% |